Guanylyl Cyclase 2C–Targeted Chimeric Antigen Receptor T-Cell Therapy in Patients With Metastatic Colorectal Cancer
Journal of Clinical Oncology · 20.07.2026 · 44 (21) · 2006-2016
DOI: 10.1200/jco-25-01090 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.07.2026. Verfasst von Changsong Qi und 24 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Key Laboratory of Cell and Gene Therapy for Solid Tumor, State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers,…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Receptors, Enterotoxin, Receptors, Chimeric Antigen, Immunotherapy, Adoptive. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE The clinical efficacies of third- or later-line therapies for metastatic colorectal cancer (CRC) are extremely limited. The purpose of this study was to evaluate the safety and efficacy of a chimeric antigen receptor T (CAR T) cell targeting guanylyl cyclase 2C (GUCY2C) that was steadily expressed in all stages of CRC in a phase I study. PATIENTS AND METHODS This was an open-label, single-center, phase I study, consisting of a 3 + 3 pattern dose-escalation phase and a dose-expansion investigation. Tumor tissues were histologically confirmed positive for GUCY2C expression. Four dose levels were tested in the dose-escalation phase, including 3 × 10 8 (DL1), 6 × 10 8 (DL2), 12 × 10 8 (DL3), and 20 × 10 8 (DL4) CAR T cells. The primary end points were safety and tolerability within 28 days after the first infusion. RESULTS In the dose-escalation phase, dose-limiting toxicity was not observed. DL3 was chosen for dose-expansion study. A total of 20 patients with metastatic CRC were infused with GUCY2C CAR T after lymphodepletion, and only one patient (5.0%) showed grade 3 cytokine release syndrome and neurotoxicity. Grade 3 diarrhea occurred in 11 patients (55.0%). Of 19 evaluable patients, the objective response rate (ORR) was 26.3%, with all responding patients in DL3 and DL4 groups. Of 10 patients in the DL3 group, the ORR was 40.0% and the median progression-free survival time (mPFS) was 7.0 months. Among patients showing medium-to-high GUCY2C expression in the DL3 group, the ORR achieved 50.0% and the mPFS was 9.0 months. CONCLUSION GUCY2C CAR T showed acceptable safety profile and high response rate in patients with third- or later-line CRC, and the clinical efficacy was associated with CAR T dose level.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Beijing Key Laboratory of Cell and Gene Therapy for Solid Tumor, State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research,…
- Beijing Key Laboratory of Cell and Gene Therapy for Solid Tumor, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Early Drug Development Centre, Peking Universit…
- Beijing Key Laboratory of Cell and Gene Therapy for Solid Tumor, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Gastrointestinal Oncology, Peking University Ca…
- Beijing Imunopharm Technology Co, Ltd, Beijing, China.
ORCID-Profile: Chang Liu, Panpan Zhang, Jiarui Li, Xiaotian Zhang, Zhihao Lu, Zhi Peng, Lin Shen
Zitieren
APA
Qi, C., Liu, C., Gong, J., Wang, X., Wang, Z., Xu, T., Liu, D., Zhang, P., Li, J., Zhang, M., Zhang, X., Lu, M., Zhou, J., Lu, Z., Peng, Z., Cao, Y., Yuan, J., Wang, Y., Lu, X., …, & Shen, L. (2026). Guanylyl Cyclase 2C–Targeted Chimeric Antigen Receptor T-Cell Therapy in Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology, 44(21), 2006-2016. https://doi.org/10.1200/jco-25-01090
Vancouver
Qi C, Liu C, Gong J, Wang X, Wang Z, Xu T, et al. Guanylyl Cyclase 2C–Targeted Chimeric Antigen Receptor T-Cell Therapy in Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology. 2026;44(21):2006-2016. doi:10.1200/jco-25-01090
BibTeX
@article{Qi2026,
author = {Qi, Changsong and Liu, Chang and Gong, Jifang and Wang, Xicheng and Wang, Zhenghang and Xu, Ting and Liu, Dan and Zhang, Panpan and Li, Jiarui and Zhang, Miao and Zhang, Xiaotian and Lu, Ming and Zhou, Jun and Lu, Zhihao and Peng, Zhi and Cao, Yanshuo and Yuan, Jiajia and Wang, Yakun and Lu, Xin'an and He, Ting and Ding, Yanping and Wu, Fei and Liu, Dongqun and Li, Jian and Shen, Lin},
title = {Guanylyl Cyclase 2C–Targeted Chimeric Antigen Receptor T-Cell Therapy in Patients With Metastatic Colorectal Cancer},
journal = {Journal of Clinical Oncology},
year = {2026},
volume = {44},
number = {21},
pages = {2006--2016},
doi = {10.1200/jco-25-01090}
}
EUVIMED